Jim Birchenough
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
40
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGLS Regulus Therapeutics | Maintains: Equal-Weight | $2 → $3 | $1.49 | +101.34% | 5 | Mar 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $50.59 | +38.37% | 3 | Feb 22, 2024 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $1 | $1.74 | -42.53% | 1 | Nov 6, 2023 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $3.06 | +1,207.19% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $14.76 | +225.20% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.83 | +745.92% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $2.76 | +4,610.14% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $0.81 | +1,622.44% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $53.54 | +170.83% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $89.84 | -29.88% | 5 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $44.82 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $5.56 | +907.19% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $828.84 | -11.44% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $7.09 | +2,438.79% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $7.51 | +339.41% | 3 | Jun 28, 2018 |
Regulus Therapeutics
Mar 13, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $1.49
Upside: +101.34%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $50.59
Upside: +38.37%
Sangamo Therapeutics
Nov 6, 2023
Downgrades: Equal-Weight
Price Target: $1
Current: $1.74
Upside: -42.53%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $3.06
Upside: +1,207.19%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $14.76
Upside: +225.20%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.83
Upside: +745.92%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $2.76
Upside: +4,610.14%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $0.81
Upside: +1,622.44%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $53.54
Upside: +170.83%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $89.84
Upside: -29.88%
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $44.82
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $5.56
Upside: +907.19%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $828.84
Upside: -11.44%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $7.09
Upside: +2,438.79%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $7.51
Upside: +339.41%